Table 1 Inquiries and approvals for Ranibizumab according to the type of retinal disease, age and gender (source: authors’ analysis of data from Clalit Mushlams’ cohort of members funding applications, March 1, 2012 to December 31, 2015]
| Â | AMD | Other CNV | RVO | DME | Other | Complex Dx | Total |
|---|---|---|---|---|---|---|---|
n = 3445 | n = 16 | n = 467 | n = 1365 | n = 25 | n = 324 | n = 5642 | |
Age - years, mean ± SD | 79.7 ± 9.02 | 71.6 ± 11.02 | 61.1 ± 15.61 | 66.7 ± 9.12 | 71.1 ± 12.29 | 70.0 ± 7.73 | 75.3 ± 11.13 |
Gender-female, n(%) | 1919 (56%) | 8 (50%) | 234 (50%) | 560 (41%) | 12 (48%) | 134 (41%) | 2867 (51%) |
Total Inquiries, n | 11,107 | 24 | 1054 | 3053 | 31 | 1509 | 16,778 |
Approved inquiries, n(%) | 8700 (78%) | 19 (79%) | 900 (85%) | 2575 (84%) | 0 (0%) | 1084 (72%) | 13,278 (79%) |